Antibody-drug conjugates
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
... BV in combination with chemotherapy has been re- ported to optimize the frontline treatment of newly diag- nosed advanced stage HL. This report was from the international randomized phase III trial (ECHELON-1, ...
17
Antibody Drug Conjugates: A Leap Ahead in Cancer Treatment
... Antibody drug conjugates comprises of a MAb chemically coupled to a linker and a cytotoxic drug ...intracellular drug release followed by antigen-specific binding and internalization of ...
8
ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1
... Antibody-drug conjugates (ADCs) are a promising new class of anti-cancer therapeutics that aim to selectively deliver potent toxins to tumor cells by using monoclonal antibodies (mAbs) as targeting ...
10
MALDI-MS: a Rapid and Reliable Method for Drug-to-Antibody Ratio Determination of Antibody-Drug Conjugates
... anticancer drug conjugated to the monoclonal antibody, called drug-to-antibody ratio (DAR), is the main quality feature of antibody-drug ...related drug-linker, in order ...
9
Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases
... Recently, antibody-directed chemotherapy has offered a very promising approach to overcome these inherent limitations of systemic chemotherapy by leveraging the targeting capability of antibodies towards ...
16
Antibody-drug conjugates--an emerging class of cancer treatment.
... Although antibody-drug conjugates (ADCs) have been under investigation for decades, it is only recently with the advent of significant advances in engineering new linker and conjugation technologies ...
6
Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology
... of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great ...an antibody and toxin-drug combined together via a chemical ...
16
Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
... The relapse rate remains high after chemotherapy for adult patients with acute lymphoblastic leukemia (ALL). With better molecular diagnosis and classification as well as better assessment for minimal residual disease, ...
13
Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates
... of antibody drug conjugates ...per antibody but also result in development of more homogenous ...on antibody reduction. After antibody reduction, the Ellman's test and SDS-PAGE ...
5
Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
... Another drug-specific AE related to GO therapy was hepatotox- icity, including the development of veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), especially after ...
13
Antibody-drug conjugates: integrated bioanalytical and biodisposition assessments in lead optimization and selection
... the drug to the antibody has been achieved through lysine or existing cysteine resi- dues resulting in heterogeneous conjugations (Casi and Neri, ...minimizing antibody scaffold modifications (Axup ...
17
Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer
... of antibody binding to RAGE ...that antibody binding location could influence receptor activation and ...following antibody binding, might therefore be an essential consideration when designing ...
18
Fate of Antibody-Drug Conjugates in Cancer Cells
... , the cytotoxicity correlated with the level of HER2 expression while the biparatopic ADC was found to be 10 times more potent than T-DM1 in HER2 overexpressing cells. In addition the biparatopic antibody could ...
12
Immunotherapeutic interventions of Triple Negative Breast Cancer
... protumourigenic effect from Tregs may serve as poten- tial immunotherapies similar to adoptive cell therapy (ACT). Moreover, the contents of the extracellular matrix (ECM), such as MMPs, prevalently change their activ- ...
19
Microtubule inhibitor-based antibody–drug conjugates for cancer therapy
... of antibody–drug conjugates (ADCs) takes advantage of the specificity of the mAb while augmenting its ability to produce a cytotoxic ...for antibody conjugation in light of their intracellular ...
10
Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer
... Antibody-directed drug delivery in the form of antibody- drug conjugates (ADC) is a promising anti-cancer strategy ...monoclonal antibody (mAb) conjugated with a highly potent ...
14
State of the art in anti-cancer mAbs
... ADC: Antibody-drug conjugates; ADCC: Antibody-dependent cellular cytotoxicity; ALCL: Anaplastic large cell lymphoma; ALL: Acute lymphoblastic leukemia; ASCT: Autologous stem cell transplant; ...
12
Dürr, Corinna (2018): Studies on the physicochemical stability of antibody conjugates. Dissertation, LMU München: Fakultät für Chemie und Pharmazie
... Antibody-drug conjugates (ADCs) combine the advantages of high target specificity and efficacious target cell ...the antibody change the stability of the parent ...IgG1 antibody at ...
127
New antibody approaches to lymphoma therapy
... targeting a desired antigen and infusion into patients with disease. Methods to potentially increase their efficacy include conjugation of mAbs with potent cell toxin or radioisotopes, exemplified by ...
12
Synthetic peptides mimicking lipopolysaccharide as a potential vaccine candidates against Vibrio cholerae serogroup O1
... using phage particles directly as a vaccine. These in- cludes: a) finding suitable host range for this type of phage libraries; b) high risk of administration of phage particles due to high amounts of exo and endotoxins ...
7